May 24, 2012 -- Frontage Chairman and CEO Song Li, Ph.D. recently provided unique perspective into navigating the Chinese business culture and operating a global pharmaceutical contract research organization.
The April 2012 video interview was conducted by Soundview Executive Insights, which offers business book summaries and other content that supports the learning and training needs of 500,000 individual and corporate international business people.
Executive Insights provides brief video interviews with business leaders and experts that have been successful in managing challenges that are discussed in the business books it summarizes. Dr. Li discussed several topics with high relevancy for today’s pharmaceutical professionals.
Frontage Laboratories, Inc. is a global contract research, development and manufacturing organization, offering a full range of pharmaceutical R&D services. Frontage operates in the US and China, using one seamless GXP platform (GMP/GLP/GCP). Frontage runs three Phase 1 Clinical units, an 88-bed Phase 1 Unit in Hackensack, NJ, a 120-bed Phase 1 Unit in Zhengzhou, Henan Province China, and a-80 bed Phase 1 Unit in Changchun, Jiling Province China. Frontage has an AALAC certified preclinical animal facility in Pennsylvania, where it also maintains bioanalytical and CMC facilities. In Shanghai and Beijing, China, the company also operates bioanalytical and CMC facilities. The Frontage CMC Division provide services in the areas of custom API synthesis and GMP manufacturing, analytical testing, formulation development and manufacturing of clinical trial materials including Sterile (Injection and Ophthalmic), Oral Solid (IR and CR), Topical, and High Potent products. As a rapidly expanding CRO with ten years of success providing high-quality GXP services, Frontage has established an international standard in pharmaceutical product research, development, quality and management systems.